• 出版社/出版日：Mordor Intelligence / 2020年9月
|Single User||￥467,500 (USD4,250)||▷ お問い合わせ|
|Team User||￥522,500 (USD4,750)||▷ お問い合わせ|
|Corporate License||￥660,000 (USD6,000)||▷ お問い合わせ|
The propelling factors for the growth of the global bioinformatics market include the increasing demand for nucleic acid and protein sequencing, increasing initiatives from government and private organizations, accelerating growth of proteomics and genomics, and increasing research on molecular biology and drug discovery. Owing to the aforementioned factors, the global bioinformatics market is expected to experience a boost during the forecast period.
Bioinformatics is gaining importance, as large amounts of data generated through techniques, like nucleic acid and protein sequencing, require data management and interpretation for future researches and medical purposes. Hence, increasing demand is expected to drive the bioinformatics market during the forecast period.
The demand for differentially expressed genes, computational epigenetics, meta-analysis of microarray data, gene network, systems biology requirements, and gene-associating studies, among others, has had a major impact on the growth of the global bioinformatics market.
There is also little research that has been done in the field of bioinformatics to expedite decision-making in healthcare. Within clinical or medical informatics, there is a rich history of research on systems designed to help care providers and patients (healthcare consumers) and make optimal decisions surrounding diagnosis and management.
[Key Market Trends]
Personalized Medicine is the Segment under Application that is Expected to Grow the Fastest During the Forecast Period
• Personalized medicine has used translational bioinformatics mostly to analyze the development of storage, analytical, and interpretive methods, so as to optimize the transformations of increasing voluminous biomedical data.
• Developments in pharmacogenomics and systems biology have helped personalized medicine to change from reductionism-based and disease-centered medical practice to system-based, integrative, and human-centered care.
• Bioinformatics is an essential component in basic research and in the development of new concepts for diagnosis and therapy, as well as in clinical practice, in which these concepts are applied to treat patients. Some of the major drivers that help in the increasing demand for bioinformatics are, growing applications of bioinformatics in drug discovery and development and growing bioinformatics support in the development of personalized medicines and clinical diagnostics.
Asia-Pacific Holds the Fastest Growth and is Expected to Follow the Same Trend over the Forecast Period
A large number of healthcare investments in the Asia-Pacific region are expected to drive the bioinformatics market. Furthermore, the high adoption of IoT technologies in this sector is expected to impact market growth in the region positively. Key countries, including China and India, are expected to propel the bioinformatics market in this region mainly.
In the north america region united states is expected to hold the major share, and this is mainly due the factors such as United States contributes majorly to the research being done in the fields of drug discovery, genomics, and proteomics structure prediction, among others, in the region, thereby boosting the growth of the bioinformatics market. A rapid expansion in pharmaceutical science, agrobiotechnology, microbial genomics, and personalized medicine has also raised revenues for the use of bioinformatics tools.
Many pharmaceutical companies are minimizing drug discovery budgets, as they are shifting their focus from outsourcing of the software to developing in-house tools, thus allowing them to customize their required applications to meet their needs and increasing workflow efficiency. The major global players in the bioinformatics market include Illumina, Thermo Fisher Scientific, and Agilent Technologies, among others.
[Reasons to Purchase this report]
• The market estimate (ME) sheet in Excel format
• 3 months of analyst support
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Demand for Nucleic Acid and Protein Sequencing
4.2.2 Increasing Initiatives from Governments and Private Organizations
4.2.3 Accelerating Growth of Proteomics and Genomics
4.2.4 Increasing Research on Molecular Biology and Drug Discovery
4.3 Market Restraints
4.3.1 Lack of Well-defined Standards and Common Data Formats for Integration of Data
4.3.2 Data Complexity Concerns and Lack of User-friendly Tools
4.4 Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 By Product and Services
5.1.1 Knowledge Management Tools
5.1.2 Bioinformatics Platform
188.8.131.52 Sequence Analysis Platform
184.108.40.206 Sequence Alignment Platform
220.127.116.11 Sequence Manipulation Platform
18.104.22.168 Structural and Functional Analysis Platform
22.214.171.124 Other Bioinformatics Platforms
5.1.3 Bioinformatics Services
126.96.36.199 Sequencing Services
188.8.131.52 Database and Management Services
184.108.40.206 Data Analysis
220.127.116.11 Other Bioinformatics Services
5.2 By Application
5.2.1 Microbial Genome
5.2.2 Gene Engineering
5.2.3 Drug Development
5.2.5 Personalized Medicine
5.2.6 Other Applications
5.3.1 North America
18.104.22.168 United States
22.214.171.124 United Kingdom
126.96.36.199 Rest of Europe
188.8.131.52 South Korea
184.108.40.206 Rest of Asia-Pacific
5.3.4 Middle East & Africa
220.127.116.11 South Africa
18.104.22.168 Rest of Middle East & Africa
5.3.5 South America
22.214.171.124 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Illumina Inc.
6.1.2 Thermo Fischer Scientific (Life Technologies)
6.1.3 Qiagen NV
6.1.4 Agilent Technologies
6.1.7 Dassault Systèmes
6.1.8 Geneva Bioinformatics SA
6.1.11 Lineage Cell Therapeutics (BioTime Inc.)
7 MARKET OPPORTUNITIES AND FUTURE TRENDS